BioFreedom French Registry

Study Overview
=================
Brief Summary
-----------------
Prospective, observational multi-center registry to be conducted at up to 25 French interventional cardiology centers. Patients will be eligible once they have received at least one BioFreedomTM DCS as per standard clinical practice and will be followed for up to 2 years post PCI for data collection. The purpose of the registry is to explore the safety and effectiveness of the BioFreedomTM DCS in standard clinical practice in France and to serve as part of Post Market Surveillance.

Detailed Description
-----------------
Prospective, observational multi-center registry to be conducted at up to 25 French interventional cardiology centers. Patients will be eligible once they have received at least one BioFreedomTM DCS as per standard clinical practice and will be followed for up to 2 years post PCI for data collection. The registry will be purely observational and will not interfere with physician's decisions relating to stent selection or indication for treatment. The purpose of the registry is to explore the safety and effectiveness of the BioFreedomTM DCS in standard clinical practice in France and to serve as part of Post Market Surveillance.

Official Title
-----------------
A Post-Market Registry of the BioFreedomTM Biolimus A9TM Coated Coronary Stent System

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients treated with one or more BioFreedom™ DCS .Patients who agree to comply with the follow up requirements. .Patients with a life expectancy of > 1 year at time of consent. .Patients eligible to receive dual anti platelet therapy (DAPT). Patients who have signed an Informed Consent Exclusion Criteria: Patients unable or unwilling to give documented informed consent Patients taking part in another interventional trial which has not completed follow-up for the primary endpoint .Patient has received an additional stent different from a BioFreedom™ DCS stent during the index procedure. Pregnant or breastfeeding women Planned surgery within 6 months of percutaneous coronary intervention (PCI) unless dual antiplatelet therapy is maintained throughout the peri surgical period for non HBR patients Planned surgery within 1 month of percutaneous coronary intervention (PCI) unless dual antiplatelet therapy is maintained throughout the peri surgical period for HBR patients Patients under judicial protection, tutorship or curatorship
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DOCE | Device-oriented composite endpoint (DOCE) at 12 months defined as composite of cardiovascular death (CD), myocardial infarction (MI) not clearly attributable to a non-target vessel and clinically driven target lesion revascularization (cd-TLR). | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality | 1. All-cause mortality, CD, non-cardiovascular and undetermined death in hospital and at 12 and 24 months | 12-month and 24-month | 
| Patient-oriented composite endpoint (POCE) at 12 and 24 months | Patient-oriented composite endpoint (POCE) at 12 and 24 months defined as all-cause mortality, any stroke, any MI (including nontarget vessel territory) and any revascularization. | 12 months and 2 years | 
| Composite of Cardiovascular Death (CD) at 12 and 24 months | Composite of CD, MI and definite/probable stent thrombosis (ST) at 12 and 24 months. | 12 months and 2 years | 
| Definite/probable ST at 12 and 24 months | Definite/probable ST at 12 and 24 months | 12 months and 24 months | 
| Target Vessel Failure defined at 12 and 24 months | Target Vessel Failure (TVF) defined as CD, target-vessel-related MI, and Target vessel revascularization (TVR) at 12 and 24 months | 12 months and 24 months | 
| Target Lesion Failure at 12 and 24 months | Target Lesion Failure (TLF) defined as CD, target-vessel-related MI, and clinically driven TLR at 12 and 24 months | 12 months and 24 months | 
| Clinically driven TLR at any follow-up time point | Clinically driven TLR at any follow-up time point | Inclusion, 12 months and 24 months | 
| Clinically driven TVR at any follow-up time point | Clinically driven TVR at any follow-up time point | Inclusion, 12 months and 24 months | 
| Any revascularization | Any revascularization within 24 months following the index procedure, unless they are planned within the 1st month | within 24 months following the index procedure | 
| Stroke, disabling and non-disabling. | Stroke, disabling and non-disabling. | Inclusion, 12 months and 24 months | 
| BARC 3 to 5 bleeding | BARC 3 to 5 bleeding | Inclusion, 12 months and 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
coronary artery disease